Document:

Master Starting Material Manufacturing (China) Agreement

 Exhibit 10.11 
 MASTER STARTING MATERIAL MANUFACTURING (CHINA) AGREEMENT 
 This Master Manufacturing Agreement
(“Agreement”) is made and entered into as of March 30, 2006 (“Effective Date”) by and between 
 WuXi PharmaTech
Co., LTD. (“Contractor”), having its principal place of business at NO. 1 Building, 288 FuTe ZhongLu, WaiGaoQiao Free Trade Zone, Shanghai, P.R. China 200131, and 
 PFIZER Inc. (“Pfizer”), having its principal place of business at 235 East
42nd Street, New York, NY USA 10017. 
 PURPOSE 
 Pfizer wishes to engage Contractor to manufacture certain starting
materials and their intermediates for Pfizer’s products and Contractor wishes to provide such services to Pfizer subject to the terms and conditions of this agreement: 
 AGREEMENT 
  

	1.	DEFINITIONS 

  

	1.1	“Affiliates” means any corporation, firm, partnership or other entity which directly or indirectly controls, is controlled by, or is under common control with the
relevant party. 

  

	1.2	“Evaluation” is defined in Section 4. 

  

	1.3	“Financial Records” is defined in Section 11.2. 

  

	1.4	“GMP” means the current good manufacturing practices for manufacturing finished pharmaceutical products as set forth in the United States Food, Drug and Cosmetic
Act and any regulation promulgated under it, in each case as amended from time to time, or the guidelines set forth by the European Union or any other foreign equivalent, including those described in the ICH Q7A guidelines. 

 

	1.5	“Hazardous Materials” means all materials capable of causing harm or injury to human health or the environment, including, without limitation, toxic, flammable, or
explosive materials; asbestos-containing materials, polychlorinated biphenyls, or lead-containing materials; and, carcinogenic, mutagenic, or teratogenic materials 

  

	1.6	“Intellectual Property” means all registerable and unregisterable intellectual property rights (including without limitation patent rights, copyrights, trademarks
and trade secrets) anywhere in the world. 

  

	1.7	“Pfizer Materials” means any raw materials or equipment supplied to Contractor by Pfizer for an Evaluation or for the manufacture of a Starting Material under any
Purchase Order. 

  

	1.8	“Product” means the active pharmaceutical ingredient to be manufactured by or on behalf Pfizer using a Starting Material supplied under a Purchase Order.

  

	1.9	“Purchase Order” means any written purchase order or work order issued by Pfizer or any Quote signed by Pfizer and issued against a purchase order, which – in
both cases – specifically reference this Agreement and includes a description of the requested Services, quantity, price, Pfizer destination, and requested delivery date. A form of work order is attached as Schedule B, but this is an example
only and Purchase Order does not need to be in this form to be a valid Purchase Order under this Agreement. 

  

	1.10	“Quote” means a written price quotation issued by Contractor in response to a request from Pfizer. The quote will include any proposal by the Contractor to apply
any intellectual property owned or controlled by it in the provision of the Services. 

  

	1.11	“Regulatory Standards” means requirements of the United States or foreign equivalent license requirements for the Contractor’s facility, and all other laws or
regulations applicable to Contractor, the Contractor’s facility, and Contractor’s manufacture, storage, packaging, labeling, testing, control and shipment of Starting Material. 

  

	1.12	“Services” is defined in Section 2. 

  

	1.13	“Specifications” means for any Starting Material, the manufacturing, analysis, testing, quality, handling, shipping and storage specifications, plus any documentary
requirements, set out in the Purchase Order or otherwise specified by Pfizer in writing. 

  

	1.14	“Starting Material” means a compound – or its intermediates – to be supplied to Pfizer under a Purchase Order for use in the manufacture of a Product,
where the compound and its method of manufacture is not subject to GMP. 

  

	2.	SCOPE OF AGREEMENT 

  

	2.1	Under this Agreement Pfizer may request Contractor to manufacture Starting Materials from time to time (“Services”). 

  

	2.2	The parties agree that: 

  

	 	(a)	any Materials, Intellectual Property or technology transferred by Pfizer to the Contractor under this Agreement is for the sole purpose of the Contractor providing the Services to
Pfizer and the Contractor is not the end user of such Materials, Intellectual Property or technology; 

  

	 	(b)	the Contractor is not required to pay Pfizer for the transfer of any Materials, Intellectual Property or technology provided by Pfizer to the Contractor under this Agreement; and

  

	 	(c)	the Contractor’s sole compensation for provision of the Services is set out in Section 3 and the Contractor is not entitled to charge Pfizer for any improvements or new
Intellectual Property relating to the Materials or Specifications. 

  

	3.	PURCHASE ORDERS 

  

	3.1	The Contractor will issue a Quote for any Services requested by Pfizer. Pfizer will accept a Quote by either issuing a Purchase Order for the Services, or returning the Quote signed
by Pfizer and referencing the applicable Purchase Order. The Contractor may only initiate the Services after Pfizer accepts the applicable Quote. The terms of this Agreement will take precedence over any printed terms on any purchase orders, quotes,
invoices or other documentation issued in relation to Starting Materials by either party. 

  

	3.2	Any affiliate of Pfizer may execute a Purchase Order under this Agreement, without requiring Pfizer or the Contractor to be a signatory to that Purchase Order.

  

	4.	EVALUATION 

  

	4.1	Before Pfizer requests any Services with respect to a particular Starting Material, Pfizer may provide Contractor with information on, and samples of, the Starting Material and its
method of manufacture so that both parties can evaluate Contractor’s capabilities and interest in providing Services (“Evaluation”). 

  

	4.2	On Pfizer’s request, Contractor will provide Pfizer with a written report detailing the results of the Evaluation including, any test data, process improvements or proposals to
apply intellectual property owned or controlled by Contractor. 

  

	5.	MANUFACTURE AND SUPPLY 

 Contractor will manufacture
the Starting Materials in strict accordance with the Specifications and the Regulatory Standards. Contractor will supply Starting Material to Pfizer in the quantities, on the schedule and at the price stated in the Purchase Order. Contractor will
store all starting materials and in-process products in accordance with the Specifications. 
  

	6.	SHIPPING 

 Contractor will package, insure and ship
the Starting Material in accordance with the instructions stated in the Purchase Order. 
  

	7.	PAYMENT 

  

	7.1	Pfizer will pay Contractor for the Services as stated in the Purchase Order. 

  

	7.2	Unless otherwise stated in the applicable Purchase Order, Contractor will invoice Pfizer on completion of the Purchase Order and Pfizer will pay undisputed invoices within 30 days
of its receipt by Pfizer. All invoices must reference the Pfizer Purchase Order number and must be sent to the address specified in the applicable Purchase Order. 

  

	7.3	Contractor shall be responsible for all national, state and/or local sales, use, value-added or other taxes or fees that Contractor may be required to pay or to collect for the
performance of the Services and/or profit it realizes under this Agreement. 

  

	8.	PFIZER MATERIALS 

  

	8.1	Pfizer Materials will remain Pfizer’s property at all times and will only be used by the Contractor for the purposes of manufacturing Starting Material under the relevant
Purchase Order. 

  

	8.2	Contractor must store and maintain Pfizer Materials in such a way that they are clearly identifiable as Pfizer’s property. Contractor must not transfer to another site or party
or destroy or dispose of Pfizer Materials or Starting Materials without Pfizer’s written consent. 

  

	9.	EH&S COMPLIANCE 

  

	9.1	The Contractor must carry out the Services in a safe manner and in compliance with all applicable environmental, health and safety laws. This obligation will not be subject to
Section 26.6 – Force Majeure. Contractor will be solely responsible for any liability arising out of the generation, handling, storage, treatment, or disposal of any Hazardous Materials generated or used in the Services.

  

	9.2	When requested by Pfizer, Contractor must promptly give Pfizer all relevant environmental and health and safety information related to the operation of its facilities used for the
Services. Pfizer will give the Contractor the environmental and health and safety information described in the Purchase Order and the Specifications. 

  

	9.3	Contractor must – in connection with the Services or facilities used for the Services - give Pfizer prompt written notice of any material non-compliance with applicable
environmental, health and safety laws that pose a significant threat to the environment, health or safety. 

  

	9.4	If Pfizer notifies Contractor that its conduct of the Services or its operation of the facilities used for the Services does not comply with all applicable environmental health and
safety laws, the Contractor must correct the non-compliance in accordance with the Specifications. 

  

	10.	AUDIT 

  

	10.1	Pfizer may audit Financial Records and the records described in Section 11.1 and monitor and audit the Contractor’s conduct of the Services to verify compliance with this
Agreement (including, without limitation, its compliance with Section 9). Such auditing and monitoring will take place on reasonable notice as Pfizer reasonably thinks fit, including the right to inspect any facility being used by Contractor
for the Services and to inspect all relevant records. Pfizer will endeavour to agree a mutually acceptable time with the Contractor for such inspections. Contractor will co-operate fully with Pfizer during audits performed under this Section,
including furnishing to Pfizer copies of all requested documents. 

  

	10.2	Contractor shall notify Pfizer of any regulatory inspection that may bear on the Product or starting material within one business day of Contractor’s learning of such
inspection. Contractor shall provide Pfizer with copies of all inspection documents related to Product or starting material within two weeks of Contractor’s receipt of such documents. 

  

	11.	RECORDS 

  

	11.1	Unless stated otherwise in the Purchase Order, Contractor will, at its expense, store all batch records, quality assurance records, analytical procedures, testing, and quality
control records relating to a particular Purchase Order for five (5) years following completion of the Purchase Order at which time the Pfizer should be notified to determine whether the records may be destroyed or continue to be stored at
Pfizer’s request or expense. 

  

	11.2	Contractor will maintain, in accordance with Generally Accepted Accounting Principles and Practices, records reflecting the accuracy of Contractor’s charges, including invoices
for compensation, and other information as Pfizer may reasonably require in connection with this Agreement (“Financial Records”). Contractor will preserve such documents, without receipt of additional compensation, for at least three years
after the date of the final payment. 

  

	12.	REJECTION OF STARTING MATERIAL 

  

	12.1	Pfizer will have the right to reject any Starting Material that has not been manufactured in compliance with Contractor’s warranty in Section 18, without invalidating the
remainder of the relevant order. 

  

	12.2	Any quantities of Starting Material that are rejected pursuant to this section will be returned to Contractor for reprocessing, re-working or replacement by Contractor at
Contractor’s sole cost and expense. Contractor will obtain approval from Pfizer, in writing, prior to commencing any such work. If such work is requested by Contractor, and agreed to by Pfizer, Contractor shall be responsible for all costs and
expenses incurred in connection therewith. The Contractor will be responsible for the replacement cost of any Pfizer Materials rendered unusable by the Contractor’s failure to comply with its warranty in Section 18.

  

	12.3	If Contractor disputes Pfizer’s basis for rejecting Starting Material, then the rejected Starting Material will be tested by an independent laboratory nominated by Pfizer. The
independent laboratory’s determination will be final and binding on the parties. The cost of such testing will be borne by Contractor if the independent laboratory confirms that the Starting Material in question does not comply with
Contractor’s warranty in Section 18. Otherwise the costs will be borne by Pfizer. 

  

	13.	INTELLECTUAL PROPERTY 

  

	13.1	Pfizer will retain ownership of any Intellectual Property in the information disclosed for any Evaluation, the Specifications and Pfizer Materials. Except for the limited purpose of
performing its obligations under this Agreement and except as provided under 13.4 and 13.5, neither party is granted any right, title or interest in any Intellectual Property owned or controlled by the other. 

  

	13.2	Before any employee, permitted subcontractor or agent commences work on any Services the Contractor must obtain from all employees, contractors or agents, in form and substance
reasonably satisfactory to Pfizer; 

  

	 	(a)	a valid prospective deed of assignment under the China Patent Act for all Intellectual Property covering the Starting Material or its method of manufacture produced in performance
of an Evaluation or Services; 

  

	 	(b)	a power of attorney irrevocably designating and appointing Pfizer and its duly authorized officers and agents as the employee’s, contractor’s or agent’s
attorney-in-fact to file any deeds or applications on their behalf in respect of any assignment of Intellectual Property covering the Starting Material or its method of manufacture produced in performance of an Evaluation or Services.

  

	13.3	Contractor irrevocably designates and appoints Pfizer and its duly authorized officers and agents as its agent and attorney-in-fact, to act for and in its behalf and stead to
execute and file any documents and to do all other lawfully permitted acts for Intellectual Property covered by Section 13.4(a) with the same legal force and effect as if executed by the Contractor. 

  

	13.4	If Contractor produces Intellectual Property covering the Starting Material or its method of manufacture in performance of an Evaluation or Services under a Purchase Order:

  

	 	(a)	Contractor agrees that any such Intellectual Property will as between Pfizer and Contractor, will belong to Pfizer. All inventions produced by Contractor in performance of the
manufacture of Products under a Purchase Order are service invention creations and, therefore, as between the Contractor and its employees, contractors or agents belong to the Contractor. The Contractor perpetually and irrevocably assigns to Pfizer,
all worldwide rights in such Intellectual Property. 

  

	 	(b)	Pfizer grants Contractor a world wide, royalty free, irrevocable, non-exclusive license – including the right to sublicense – to use such Intellectual Property for all
purposes other than (i) the manufacture of the Starting Material for third parties; or (ii) the manufacture of a compound to be used in the manufacture of a pharmaceutical active ingredient that has the same indication or mechanism of
action as the Pfizer Product. If Contractor is uncertain of the indication or mechanism of action of the API related to the Compound then Pfizer will provide this information upon request by Contractor. 

  

	13.5	If Contractor would like to use Intellectual Property owned or controlled by it in the manufacture of a Starting Material it must notify Pfizer in writing outlining the nature of
the intellectual property and obtain Pfizer’s prior written consent. 

  

	 	(a)	Any such Intellectual Property must be detailed in the Purchase Order. 

  

	 	(b)	If Pfizer consents to the use of the Intellectual Property, Contractor agrees not to unreasonably withhold the rights for Pfizer and its licensees use of the Intellectual Property
in the manufacture of the Starting Material, on terms to be negotiated in good faith. 

  

	 	(c)	 If Contractor does not obtain Pfizer’s prior written consent before using such Intellectual Property in the manufacture of a Starting Material under a 

	 	 
Purchase Order, Contractor agrees that neither it nor any assignee or licensee of Contractor, will enforce such Intellectual Property to prevent Pfizer and
its licensees from using the Intellectual Property in the manufacture of the Starting Material for Pfizer. 

  

	 	13.6	Contractor must not file a patent application anywhere in the world claiming the use or method of manufacture of any Starting Material or its intermediates.

  

	 	13.7	Notwithstanding the provisions of the China Copyright Act, the assignment to Pfizer of all Intellectual Property under this Agreement will not lapse nor will the Intellectual
Property revert to the Contractor or its employees, contractors or agents even if Pfizer does not exercise the rights under assignment within a period of one (1) year from the date of this assignment. 

  

	14.	REGULATORY 

 Pfizer will be responsible for
preparation of regulatory submissions relating to Product marketing approval (e.g., INDs and NDAs). Upon request by Pfizer, Contractor shall provide reasonable assistance with such submissions in connection with any documentation provided by
Contractor hereunder, at a rate specified in an approved Proposal. 
  

	15.	CONFIDENTIALITY 

  

	15.1	For purposes of this Agreement, the term “Confidential Information” will mean information disclosed to Contractor for an Evaluation, the Specifications, Pfizer Materials,
information relating to the Starting Material and its manufacture produced by Contractor in performance of any Purchase Order, all written information which Pfizer delivers to Contractor pursuant to this Agreement stamped or otherwise identified in
writing on the document “Confidential,” and all oral information which Pfizer declares to be confidential and confirms such declaration in writing within 30 days of disclosure; and 

  

	15.2	Contractor will maintain the Information in confidence with the same degree of care it holds its own confidential information. Contractor will only use the Confidential Information
for the purposes of performing its obligations or exercising its rights under this Agreement. Contractor will not disclose the Confidential Information to any third party and will only disclose the Confidential Information to its officers and
employees that need for the purposes of performing its obligations or exercising its rights under this Agreement. 

  

	15.3	Contractor’s obligation of nondisclosure and the limitations upon the right to use the Confidential Information shall not apply to the extent that Contractor can demonstrate
that the Confidential Information: 

  

	 	(a)	was in the possession of Contractor prior to the time of disclosure; or 

  

	 	(b)	is or becomes public knowledge through no fault or omission of Contractor; or 

  

	 	(c)	is obtained by Contractor from a third party under no obligation of confidentiality to Pfizer; or 

  

	 	(d)	if Contractor is requested or ordered to disclose the Information in connection with a legal or administrative proceeding, Contractor will give Pfizer prompt notice of such request.
Pfizer may seek an appropriate protective order or other remedy or waive compliance with the provisions of this Agreement or both. If Pfizer seeks a protective order or other remedy, Contractor will cooperate with Pfizer. If Pfizer fails to obtain a
protective order or waive compliance within the relevant provisions of this Agreement, Pfizer will disclose only that portion of Confidential Information which its legal counsel determines it is required to disclose. 

  

	15.4	All confidentiality obligations of under this Agreement will survive the termination of this Agreement for a period of *. 

  

	16.	RELATIONSHIP WITH PFIZER 

  

	16.1	Contractor is an independent contractor and acknowledges that Contractor, its personnel, or employees are not employees of Pfizer. Accordingly, neither Contractor nor its employees
or personnel will (a) participate in Pfizer employee benefit plans nor receive any other compensation beyond that stated below, (b) have the power or authority to bind Pfizer or to assume or create any obligation or responsibility, express
or implied, on Pfizer’s part or in Pfizer’s name, except as otherwise set forth in this Agreement, or (c) represent to any person or entity that Contractor, its personnel or any employee of Contractor has such power or authority.
Contractor will remain solely liable for all aspects of the employment of such persons including, without limitation, recruitment, hiring, firing, training, promotion, compensation, all payroll taxes and other deductions and all premiums or payments
made for workers’ compensation coverage, unemployment benefits or any other payments required by law to be made by employers for or on behalf of employees. 

  

	16.2	Contractor represents and warrants that it and its personnel, and employees are authorized to perform the Services and that neither it nor its personnel or employees will act in
violation of any applicable immigration laws or regulations. Contractor will indemnify Pfizer against any and all claims, fines, penalties and/or attorneys’ fees incurred by Pfizer for breach by Contractor of any immigrations laws or
regulations and of this warranty. 

  

	17.	SUBCONTRACTING 

  

	17.1	Contractor may not utilize subcontractors to perform any part of the Services or Evaluation, including analytical testing, without prior written authorization by Pfizer.

  

	17.2	Contractor will be responsible and liable for any authorized subcontractor’s performance of the Services and compliance with this Agreement. Contractor must ensure that any
authorized subcontractor is, and remains, insured in accordance with Schedule A. 

  

	 *
	 Indicates that certain information contained herein has been omitted and filed
separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

	18.	CONTRACTOR WARRANTIES 

 Contractor represents,
warrants and covenants that: 
  

	 	(a)	all Starting Material supplied to Pfizer under this Agreement will meet the Specifications; 

  

	 	(b)	it has the right and authority to enter into and perform its obligations under this Agreement, and 

  

	 	(c)	it will perform all of its obligations under this Agreement in accordance with all applicable governmental laws, rules and regulations; 

  

	 	(d)	any authorized subcontractor will comply with the terms of this Agreement; and 

  

	 	(e)	it will carry out the Services in a safe manner and in compliance with all applicable environmental, health and safety laws. 

  

	19.	PFIZER WARRANTIES 

 Pfizer represents, warrants and
covenants that: 
  

	 	(a)	it has the right and authority to enter into and perform its obligations under this Agreement; and 

  

	 	(b)	it will perform all of its obligations under this Agreement in accordance with all applicable governmental laws, rules and regulations. 

  

	20.	INDEMNIFICATION BY CONTRACTOR 

  

	20.1	Contractor will defend, indemnify and hold harmless Pfizer and its Affiliates, and its or their officers, directors, shareholders, employees, agents and representatives from and
against any and all liability, damage, loss, cost or expense (including reasonable attorney’s fees, costs and amounts paid in settlement) (collectively, “Losses”) resulting from any third party claim made or suit brought against
Pfizer or any such persons arising out of Contractor’s breach of any of its representations, warranties or covenants in Section 18. 

  

	20.2	Upon receipt of notice of any such claim or suit, Pfizer will promptly notify Contractor thereof and will permit Contractor, at its cost, to handle and control such claim or suit.
Pfizer will have the right to participate in the defense of such claim or suit at its own expense. Pfizer shall afford Contractor all reasonable assistance (at Contractor’s cost and expense) and will make no admission prejudicial to the defense
of such claim or suit. 

  

	20.3	The foregoing indemnification obligation will not apply to any claim or suit to the extent it arises directly out of Pfizer’s negligence, willful misconduct or breach of any
term, representation, warranty or covenant contained in this Agreement. 

	21.	INDEMNIFICATION BY PFIZER 

  

	21.1	Pfizer will defend, indemnify and hold harmless Contractor and its Affiliates, and its or their officers, directors, shareholders, employees, agents and representatives from and
against any and all liability, damage, loss, cost or expense (including reasonable attorney’s fees, costs and amounts paid in settlement) (collectively, “Losses”) resulting from any third party claim made or suit brought against
Contractor or any such persons arising out of (a) Pfizer’s breach of any of its representations, warranties or covenants in Section 19; or (b) the use by Pfizer of any Starting Material supplied by Contractor under this Agreement
that complies with its applicable Specifications. 

  

	21.2	Upon receipt of notice of any such claim or suit, Contractor will promptly notify Pfizer thereof and will permit Pfizer, at its cost, to handle and control such claim or suit.
Contractor will have the right to participate in the defense of such claim or suit at its own expense. Contractor will afford Pfizer all reasonable assistance (at Pfizer’s cost and expense) and will make no admission prejudicial to the defense
of such claim or suit. 

  

	21.3	The foregoing indemnification obligation will not apply to any claim or suit to the extent it arises directly out of Contractor’s negligence, willful misconduct or breach of
any term, representation, warranty or covenant contained in this Agreement. 

  

	22.	INSURANCE 

 Contractor will provide and maintain
such insurance coverage, in minimum types and amounts as described in Schedule A. Contractor will on Pfizer’s request produce original certificates and additional insurance endorsements evidencing the specified insurance coverage, prior to
execution of this Agreement, and, upon renewal of this Agreement or expiration of any one coverage, whichever comes first. Coverage shall be maintained for the duration of the Agreement or as specified in Schedule A. 
  

	23.	LIMITATION OF LIABILITY 

 Neither party will be
liable to the other under this Agreement, whether in tort, contract or otherwise, for any indirect or consequential losses or any punitive or exemplary damages. 
  

	24.	PUBLICITY 

  

	24.1	No press releases or other statements in connection with this Agreement intended for use in the public or private media shall be made by Pfizer or Contractor without the prior
written consent of the other party. If either party is required by law or governmental regulation to describe its relationship to the other, it will promptly give the other party notice with a copy of any disclosure it proposes to make.

  

	24.2	In addition, Contractor will not use Pfizer’s name in connection with any products, services, promotion, or advertising without Pfizer’s prior written permission.

	25.	TERM AND TERMINATION: 

  

	25.1	This Agreement will expire 5 years from the Effective Date. 

  

	25.2	Pfizer may terminate: 

  

	 	(a)	any Purchase Order *, or 

  

	 	(b)	this Agreement *. 

 If Pfizer terminates this Agreement or
any Purchase Order without cause, Pfizer’s only obligation will be to pay Contractor for the services completed or unavoidable costs incurred and documented in accordance with the relevant Purchase Order under the Agreement or the terminated
Purchase Order, as the case may be, up to the date of termination, at the rates provided in the Purchase Order. All payments paid to the Contractor in excess of those due to it under this Section will be returned to Pfizer. 
  

	25.3	If either party breaches this Agreement, the other may terminate it if the breaching party does not cure the breach within thirty (30) days of written notice of same.
Termination will be without prejudice to any rights which may have been accrued to either party before termination. 

  

	25.4	On termination of this Agreement for any reason Contractor will return, at Pfizer’s expense, all Pfizer Materials. In addition the parties will return to each all copies of the
other party’s Confidential Information except for one copy which may be retained for the sole purpose of determining continuing obligations under Section 13. Contractor will ensure any Confidential Information which is not in a returnable
form, such as that detailed in Contractor’s laboratory notebooks, plant batch records or computerised data, be deleted where practical or otherwise marked as Pfizer Confidential and remain covered by this agreement as detailed in clause 13.

  

	25.5	Termination of this Agreement will be without prejudice to the rights and obligations of the parties set forth in Sections 9 and 12 and any Sections which provide by their terms
performance by either party subsequent to termination 

  

	26.	GENERAL 

  

	26.1	Assignment. Contractor will not transfer or assign its rights or obligations under this Agreement, in whole or in part, without Pfizer’s prior written permission. Pfizer
may assign its rights and obligations under this Agreement to any Affiliate without Contractors prior consent. 

  

	26.2	Entire Agreement; Amendments. The provisions, terms and conditions of this Agreement (including its schedules) and any Quote and Purchase Order constitute the entire
agreement of the parties with regard to the subject matter of this Agreement and supersede any prior agreements whether oral or written. No waiver, modification, change or amendment of any of the provisions of this Agreement shall be valid unless in
writing and signed by the party against whom such claimed waiver, modification, change or amendment is sought to be enforced. 

  

	 *
	 Indicates that certain information contained herein has been omitted and filed
separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

	26.3	Notices. All notices, requests, demands and other communications required or permitted to be given hereunder will be in writing and will be deemed to have been given
(a) when received, if delivered in person, or (b) when sent, if send by facsimile with receipt confirmed, or (c) three (3) business days following the mailing thereof, if mailed by certified first class mail, postage prepaid,
return receipt requested, in any such case as follows: 

  

			
	If to PFIZER:	  	Pfizer Global R&D Headquarters
		  	50 Pequot Avenue
		  	New London, CT 06320
		  	Attn.: Executive Vice President, PGRD
		  	with copy to: General Counsel, PGRD
		
	If to Contractor:	  	WuXi PharmaTech Co., LTD.
		  	No. 1 Building, 288 FuTe ZhongLu,
		  	WaiGaoQiao Free Trade Zone,
		  	Shanghai, P.R. China 200131

  

	26.4	Severability. If any term or provision of this Agreement is invalid or unenforceable, the remainder of this Agreement shall be unaffected thereby and each remaining term or
provision of this Agreement is valid and will be enforceable to the fullest extent permitted by law. 

  

	26.5	Waiver. The failure of either party to insist upon strict observation or performance of any provision of this Agreement, or to exercise any right or remedy shall not impair
or waive any such right or remedy in the future. Every right and remedy given by this Agreement to the parties may be exercised from time to time as often as appropriate. All remedies, either under this Agreement or by law or otherwise afforded,
will be cumulative and not alternative. 

  

	26.6	Force Majeure. Neither party will be liable nor deemed to be in default for any delay or failure in performance under this Agreement or other interruption of service or
employment deemed resulting directly or indirectly from Acts of God, civil or military authority, acts of public enemy, war, accident, fire, explosion, earthquake, flood, failure of transportation, strike, or other work interruption by either
party’s employees or any similar or dissimilar cause beyond the reasonable control of either party. 

  

	26.7	Binding Effect. This Agreement will be binding upon and will inure to the benefit of Pfizer and Contractor, their respective successors and permitted assigns.

	26.8	Dispute Resolution and Jurisdiction. CONTRACTOR HEREBY EXPRESSLY ACKNOWLEDGES AND AGREES THAT THE UNMODIFIED TERMS AND CONDITIONS OF THE DISPUTE RESOLUTION PROVISIONS SET
OUT IN SCHEDULE C ARE A MATERIAL AND ESSENTIAL PART OF THIS AGREEMENT, SERVED AS A MATERIAL INDUCEMENT TO PFIZER’S ENTERING INTO THIS AGREEMENT AND THAT PFIZER WOULD NOT HAVE ENTERED INTO THIS AGREEMENT OR AGREED TO BE BOUND TO ANY OTHER TERMS
OR CONDITIONS GOVERNING DISPUTE RESOLUTION. NO COURT SHALL HAVE ANY JURISDICTION WHATSOEVER EXCEPT AS EXPRESSLY PROVIDED UNDER SECTION 1(G) OF SCHEDULE C. 

  

	26.9	Headings. The heading of this Agreement are inserted merely for convenience and ease of reference and will not affect or modify the meaning of any of the terms, covenants or
conditions of this Agreement. 

 IN WITNESS WHEREOF the parties have caused this Agreement to be executed and delivered
by their duly authorized representatives. 
  

									
	WuXi PharmaTech Co., LTD.	 		 	Pfizer Inc
					
	By:	 	  
	 		 	By:	 	  

	Name:	 	  
	 		 	Name:	 	  

	Title:	 	  
	 		 	Title:	 	  

	Date:	 	  
	 		 	Date:	 	  

 Schedule A 
 INSURANCE REQUIREMENTS 
 1. Employer’s Liability Insurance with a limit of not less than *.

 2. Voluntary Compensation insurance covering all employees not subject to the applicable state Workers’ Compensation Act or Acts.

 3. Commercial General Liability insurance with the following limits and forms/endorsements: 
 Each
Occurrence                                      
              * 
 Products and Completed Operations
Aggregate    * 
 4. If the Contractor will bring vehicles onto a Pfizer site or use vehicles to perform the
Services, Automobile and Truck Liability Insurance in the amount of * combined single limit for bodily injury and property damage arising out of all owned, non-owned and hired vehicles. This must cover all automotive and truck equipment used
in the performance of the Services under this Agreement both on and off the work site, and must include the loading and unloading of same. 
 5. If Contractor has care, custody or control of Pfizer property or inventory, Contractor shall be responsible for any loss or damage to it, and provide all risk Property Coverage at full replacement cost for same. 
 Any and all deductibles for such insurance policies shall be assumed by, for the account of, and at the Contractor’s sole risk. All deductibles and
self-insured retention amounts must be acceptable to and approved, in writing (if required), by Pfizer. 
  

	 *
	 Indicate that certain information contained herein has been omitted and filed
separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Schedule B 
 WORK ORDER TEMPLATE for MASTER STARTING MATERIAL MANUFACTURING AGREEMENT 
 THIS WORK ORDER is made on
[date] 
 BETWEEN 
  

	(1)	PFIZER [entity] (“Pfizer”), having its principal place of business at [Insert Details]; and 

  

	(2)	[CONTRACTOR NAME] (“Contractor”), having its principal place of business at [Insert Details] 

 WHEREAS 
 This Work Order is entered into pursuant to the
Master Starting Material Manufacturing Agreement dated [    ] between Pfizer and the Contractor (the “Agreement”). The terms and conditions of the Agreement govern this Work Order in respect of the
Services with the following additional provisions applying: 
 1. Description of Services 
 Pfizer would like to engage the services of the Contractor for the purpose of manufacturing Pfizer’s Starting Material [compound number]. 
 2. Specification 
 [Include information regarding 
  

	 	•	Starting Material product quality specification / Material Alert Level 

  

	 	•	any Manufacturing requirements / specifications 

  

	 	•	any Handling requirements / specifications 

  

	 	•	any standard operating procedures or guidelines for the manufacture of Product which the Contractor should follow 

  

	 	•	any Packaging requirements / specifications 

  

	 	•	any In-Process Testing requirements 

  

	 	•	any Finished Goods Testing requirements 

  

	 	•	any EHS/safety requirements 

  

	 	•	Shipping instructions (Instructions to Overseas Suppliers for international shipments) 

  

	 	•	requirement to provide Certificate of Origin 

  

	 	•	requirement to provide TSE/BSE statements / certificates 

  

	 	•	requirement to provide certificates of analysis 

  

	 	•	requirement to provide Material Safety Data Sheets 

  

	 	•	any other special requirements] 

 3. Fees

  

	 	The	Purchase Order number is: The purchase order number should be quoted on all correspondence and on the invoice. 

  

 The Target Quantity is: *kg. 
 *% of the Target Quantity is: *kg. Note: * kg is *% of * kg. Delete this line if order is raised as * basis. 
 The * for this order is: 
 The full
order value is: 
 The Basis of this order is: [* or *] 
 Incoterm (2000): 
 The Tariff Code for this
Starting Material is: 
 The Delivery Date is: 
 The Starting Material Delivery Address is: 
 The invoice should be sent to: [insert EFSS address or NASS
address or other] 
 OPTIONAL 
 Use this paragraph for orders raised as campaign basis (if per kg basis delete this paragraph): 
 Pfizer shall pay the Contractor for the manufacture and delivery of the Compound to nominated location(s). The order is on a * for a *. Should the Contractor produce a quantity greater than the Target Quantity the
excess material will be supplied to Pfizer at no extra charge. Should the Contractor supply less than the Target Quantity then Pfizer will pay the full order value (i.e. assuming the Target Quantity had been supplied) for any
quantities supplied in the range of *% or greater of the Target Quantity. Should the Contractor supply less than *% of the Target Quantity Pfizer will pay for that quantity supplied at the *of this order or, if both
Pfizer and Manufacturer agree, the Contractor may undertake a further campaign to make up the shortfall to the Target Quantity at the Contractor’s cost. 
 OR 
 Use this paragraph for orders raised as * (if * delete
this paragraph): 
 Pfizer shall pay the Contractor, for the manufacture and delivery of the Compound to Pfizer’s Sandwich site, for that
quantity supplied, up to and including the Target Quantity, at the * of this order. 
 4. Pfizer Materials 

The following material(s) have been, or will be, issued to the Contractor by Pfizer on a free of charge basis in support of the Contractor’s
provision of Services or Evaluation. 
  

			
	 Material Supplied by Pfizer to Contractor
	  	 Quantity (kg)

		  	

 In relation to Pfizer Materials: 
  

	(i)	A Certificate of Analysis or Certificate of Conformity for each Pfizer Material, if available, will be provided by Pfizer to the Contractor. 

	(ii)	The Contractor will conduct an identity test, and if so requested by Pfizer, a laboratory use-test of the Pfizer Materials supplied before starting the manufacture of the Starting
Material. The Contractor will promptly report any adverse results of these tests and in such case obtain the consent of Pfizer before manufacturing the Starting Material. 

  

	 *
	 Indicates that certain information contained herein has been omitted and filed
separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

	(iii)	The Contractor is not liable for any defects of the Starting Material to the extent these arise from any defects in the Pfizer Materials supplied. 

  

	(iv)	Pfizer is only liable to the Contractor for direct loss suffered by the Contractor to the extent caused by defects in the Pfizer Materials supplied by Pfizer provided such loss does
not result from the negligence or breach of statutory duty or breach of this agreement by the Contractor. 

 5. Contractor
Intellectual Property 
 6. Contacts 
 The principle contacts for each of the 2 parties re communications and information provision are: Pfizer contact: 
 Contractor contact: 
 Signed by an authorised signatory: 
 For and on behalf of PFIZER 
  

									
	Signed:	 	 EXAMPLE ONLY
	 		  	Date:	 	  

	Name:	 	  
	 		  	Position:	 	  

				
	For and on behalf of Contractor’s name	 		  		 	
					
	Signed:	 	 EXAMPLE ONLY
	 		  	Date:	 	  

	Name:	 	  
	 		  	Position:	 	  

  

 Schedule C 
 DISPUTE RESOLUTION AND JURISDICTION 
  

	(a)	Disputes. If any dispute, disagreement or controversy of any nature or type arises out of or results from this Agreement, then without regard or reference to the principles
of conflicts of law or international private law or any contrary term or condition in any international treaty or convention (other than in connection with the recognition of arbitral awards as the parties have agreed herein below):

 (i) Jurisdiction/Forum. Any Dispute that cannot be resolved after at least thirty (30) calendar days of
informal negotiation between the parties shall be finally resolved by binding arbitration under the Rules of Arbitration of the China International Economic and Trade Arbitration Commission (“CIETAC”) as supplemented by clause
“(v)”, below (collectively, the “Rules”). The Rules shall apply to all Disputes whether deemed foreign or domestic. If CIETAC is found under Article 2 of the Rules not to have jurisdiction of a Dispute then the parties
consent to use of the arbitration rules of the International Chamber of Commerce (the “ICC”) and in such cases all references herein to “CIETAC” shall be deemed to be references to the ICC and all references to the
“Rules” shall be deemed to be references to the rules of the ICC. 
 (ii) Applicability of Rules. If a procedural
question or dispute arises that is not governed by the Rules, the Arbitrators (as defined below) shall make a binding determination of its resolution after affording each party an opportunity to state its preferred means of resolution. Each party
hereby expressly, irrevocably and unconditionally consents and submits to the personal jurisdiction of the CIETAC and waives and hereby affirmatively covenants not to assert their right to object to or challenge the sole and exclusive personal
jurisdiction of the CIETAC in connection with Disputes. Any controversy concerning the extent to which any Dispute is subject to the terms and conditions of this Section and/or the Rules, or concerning the applicability, interpretation, or
enforceability of this Section and/or the Rules, including any contention that all or part of these procedures are invalid or unenforceable, shall be governed by the United States Federal Arbitration Act and resolved by application to the United
States District Court for the Southern District of New York. 
 (iii) Venue, Language and Governing Law. The arbitration
described herein (the “Arbitration”) shall be conducted in the English language and all written briefs and statements prepared by the parties shall be submitted in the English language. The Arbitration shall be conducted at a
mutually agreed location in the Hong Kong Administrative Region of the People’s Republic of China (“Hong Kong”). All Disputes shall be governed by and construed in accordance with the substantive laws of the Peoples Republic of
China under the procedural requirements of the Rules, all without regard or reference to principles of conflicts of law that would result in the application of the laws of another jurisdiction, except that in applying the fairness and reasonableness
standard required by Article 53 of the Rules the Arbitrators shall look to the Rules of the ICC and the substantive laws of the State of New York, United States of America and the United States federal laws enforced and applied within. 

(iv) Arbitrators. The panel of arbitrators shall consist of three (3) neutral arbitrators who are mutually agreed upon by the
parties meeting the following criteria: (i) none of them shall be current or former employees, directors or shareholders of, or 

 
otherwise have any current or previous relationship with, either party or its respective Affiliates; (ii) one (1) Arbitrator shall be a former
judge of a U.S. state or federal court; (iii) one (1) Arbitrator shall be a person expert in pharmaceutical industry research and development; and (iv) one (1) Arbitrator shall be an attorney or senior business executive expert
in offshore services relationships between customers and vendors of science or technology services (collectively, the “Arbitrators”). If the parties cannot mutually agree on the Arbitrators within fifteen (15) business days of
the filing of the claim with the CIETAC, then the Arbitrators shall be selected under Articles 24 – 27 of the Rules. 
 (v)
Supplemental Rules. To the maximum extent permitted by Article 7 of the Rules, the following supplemental rules shall govern the conduct of the Arbitration. If there is any conflict between the Rules and this Section, the parties
intend that this Section shall prevail. The Arbitration shall be subject to the following rules: (i) the Arbitrators may not award or assess punitive damages against either party except that the Arbitrator, in his or her sole discretion, may
award reasonable costs, expenses and fees to the prevailing party; (ii) until such time as an award of costs is made by the Arbitrators, each party shall bear its own costs and expenses of the Arbitration and one-half (1/2) of the fees and
costs of the Arbitrators; (iii) time is of the essence with regard to the completion of the Arbitration and the Arbitrators shall make a final award no later than one (1) year after the filing of the initial claim with the CIETAC;
(iv) the rules of evidence shall not apply to the Arbitration; (v) each party shall be permitted to directly request limited production of documents in accordance with document discovery rules established by the Arbitrators; (vi) each
party shall be entitled to call up to ten (10) witnesses at the Arbitration; and (vii) the parties’ briefs shall not exceed twenty (20) double-spaced pages (excluding exhibits) having font no smaller then ten (10) point and
margins no smaller than one-half inch (the “Brief”); (viii) at least thirty (30) calendar days prior to the Arbitration, each party shall submit to the other party and the Arbitrators a copy of all exhibits on which such
party intends to rely in any oral or written presentation, a list of any witnesses such party intends to call at the hearing, and a short summary of the anticipated testimony of each witness and its Brief. 
 (vi) Award. The Arbitrators’ award shall be made as prescribed by Article 52 of the Rules and shall be the sole and exclusive remedy
between the parties regarding any claims, counter-claims, issues or accountings presented or pled to the Arbitrators. All costs, fees or taxes incident to enforcing the Arbitrators’ award shall be, to the maximum extent permitted by law,
charged against the party resisting enforcement. Judgment upon the award of the Arbitrators may be entered in a court of competent jurisdiction, or application may be made to such court for a judicial acceptance of the award or any order of
enforcement. Without limiting the foregoing, if and to extent that the final award of the Arbitrators is found unenforceable, either party may bring a cause of action against the other party before any court of competent jurisdiction at the domicile
of the defendant party. 
 (vii) Interim Relief. By agreeing to arbitration, the parties do not intend to waive their right to
seek preliminary, interim or partial awards including injunctive and other equitable relief. All such preliminary, interim or partial awards shall be made under Article 57 of the Rules. The Arbitrators shall have full authority to grant provisional
remedies and to award damages for the failure of any party to respect the Arbitrators’ orders to that effect. 
 (viii)
Confidentiality. In addition the confidentiality obligations of the parties set 

 
by the Rules and all confidentiality obligation hereunder, the parties agree that any Arbitration proceeding, the Arbitrators’ award and the fact itself
that there is an ongoing Arbitration between the parties as well as the contents and existence of this Agreement is to be considered confidential and held as such. 
 Services of Process. Contractor hereby designates its office at the address noted on the front page of this Agreement for service of process in any action or proceeding arising under this Agreement and
waives any international treaty provisions with respect to such service of process. Service of process in any action or proceeding arising hereunder shall be by mail only.Service Contract

 Exhibit 10.12 
 WUXI PHARMATECH CO., LTD 
 * SERVICES CONTRACT - 
 * PILOT PROJECT 
 This contract is made the 15th day of March, 2007 between Pfizer Inc., and WuXi PharmaTech Co., Ltd (“you/your”) for the provision of * services in support of Pfizer’s * Pilot Project. 
  

	1.	SERVICES 

  

	 	(a)	The scope of work for the services you will perform under this contract is described in Appendix A attached to this contract. After this contract is signed Pfizer may issue a
purchase order referencing these services. References in this contract to ‘applicable order’ will be deemed to mean this purchase order and the scope of work in Appendix A. 

  

	 	(b)	As the services you will provide under this contract are part of a larger project involving other vendors engaged by Pfizer, you may receive or transfer materials and information to
third parties as directed by Pfizer. Any materials or information you receive from such third parties will be deemed to be given to you by Pfizer. 

  

	 	(c)	You and Pfizer agree that: 

  

	 	(i)	any materials, intellectual property or technology transferred by Pfizer to you under this contract is for the sole purpose of you providing services to Pfizer and you are not the
end user of such materials, intellectual property or technology; 

  

	 	(ii)	you are not required to pay Pfizer for the transfer of any materials, intellectual property or technology provided by Pfizer to you under this contract; and

  

	 	(iii)	your sole compensation for provision of services under this contract is set out in Section 5 and you are not entitled to charge Pfizer for any improvements or new intellectual
property assigned to Pfizer under this contract. 

  

	2.	PERFORMANCE OF SERVICES 

  

	 	(a)	You must perform any services under this contract on the schedule stated in the applicable purchasing order. You must comply with any written specifications, requirements and
instructions referenced in the order. 

  

	 *
	 Indicates that certain information contained herein has been omitted and filed
separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  

 1 

	 	 (b)
	 You will not be held responsible for failures to perform or comply caused by failures of other vendors engaged by Pfizer
for the * Pilot Project. If you are unable to perform or comply you must notify Pfizer immediately and cooperate with Pfizer in good faith to resolve the
issue. 

  

	3.	OPERATING PROCEDURES & GUIDELINES 

 From
time to time, Pfizer may issue to you operating procedures or guidelines governing your conduct of services for Pfizer. If you commence any services after receiving such procedures or guidelines you will be deemed to have accepted them and you must
comply with them. If after receiving them, but before commencing any further services, you determine that you cannot comply with them, you must give Pfizer written notice. If you give such notice, Pfizer may terminate this contract and all orders
immediately. The terms of this contract will take precedence over any operating procedures or guidelines. 
  

	4.	SHIPPING 

 You must package, insure, process through
customs and ship any materials to be delivered to Pfizer under this contract as stated in the applicable order or, otherwise, in accordance with written instructions given to you by Pfizer. 
  

	5.	PAYMENT 

 All details relating to the price to be
paid by Pfizer for services under this contract, including timing, payment of taxes, invoicing procedure, discounts and taxes are set out in Appendix B. So that Pfizer can confirm that you have accurately invoiced Pfizer, you must maintain records
reflecting the accuracy of your invoices for at least three years after completion of the relevant services. 
  

	6.	PFIZER MATERIALS 

 (a) All materials and documents
Pfizer gives you will remain Pfizer’s property and must be stored and labelled so that they are clearly identifiable as Pfizer’s property. You may only use them to perform services under this contract and must not destroy them or transfer
them to another facility or party without Pfizer’s consent. 
 (b) Pfizer will insure any materials Pfizer gives you. You will not be
liable for loss or damage to them unless it is due to your negligence or willful misconduct. 
  

	7.	INTELLECTUAL PROPERTY 

 (a) Except to permit you to
perform the services under this contract, you are not granted any right in Pfizer’s intellectual property. Except as provided below, Pfizer is not granted any right in your intellectual property. 
  

	 *
	 Indicates that certain information contained herein has been omitted and filed
separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  

 2 

	 	(b)	Pfizer will own all intellectual property you produce in performance of services under this contract that covers any compounds you test, test data you produce or test methods you
develop for Pfizer. You assign all rights in any such intellectual property to Pfizer and must complete, at Pfizer’s expense, any documents required by Pfizer to affect the assignment or to otherwise support Pfizer’s registration or
prosecution of the intellectual property. 

  

	 	(c)	If Pfizer gives you materials or processes and requires you to use these in the services, then Pfizer will indemnify you against any third party claims that your use of such
materials or processes in performance of the services infringes a third party’s intellectual property rights. However, you must indemnify Pfizer against any third party claims that a third party’s intellectual property rights are infringed
either by (i) your use of materials or processes that have not been provided to you by Pfizer, or (ii) Pfizer’s use -as intended - of materials or processes delivered to Pfizer under this contract. 

  

	 	(d)	Before any employee, permitted subcontractor or agent commences work on any services you must obtain from all employees, contractors or agents, in form and substance reasonably
satisfactory to Pfizer; 

  

	 	(i)	a valid prospective deed of assignment under the China law for all intellectual property owned by Pfizer under this contract; 

  

	 	(ii)	a power of attorney irrevocably designating and appointing Pfizer and its duly authorized officers and agents as the employee’s, contractor’s or agent’s
attorney-in-fact to file any deeds or applications on their behalf in respect of any assignment of intellectual property owned by Pfizer under this contract. 

  

	 	(e)	You irrevocably designate and appoint Pfizer and its duly authorized officers and agents as your agent and attorney-in-fact, to act for and on your behalf and stead to execute and
file any documents and to do all other lawfully permitted acts for intellectual property owned by Pfizer under this contract with the same legal force and effect as if executed by you. 

  

	 	(f)	Notwithstanding the provisions of any laws in China, the assignment to Pfizer of all intellectual property under this contract will not lapse nor will the intellectual property
revert to you or your employees, contractors or agents even if Pfizer does not exercise the rights under assignment within a period of one (1) year from the date of this assignment or such other period as may be required by the law.

  

	 	(g)	You must ensure that you and your affiliates have contracts with your employees, contractors or agents, and policies and procedures, that ensure that any inventions assigned to
Pfizer under this contract are free and clear of any obligation by Pfizer to compensate the employees, contractors and agents for the inventions or to revert the inventions or any rights in the inventions to them. 

  

 3 

	 	(h)	You agree that nothing in this contract creates any liability for Pfizer to compensate, under China’s Patent Law, your or your affiliates’ employees, contractors or agents
for inventions made in performance of services under this contract. 

  

	 	(i)	You must indemnify Pfizer and its affiliates, and their officers, directors, shareholders, employees, agents and representatives from and against any liability resulting from any
claim made against Pfizer or its affiliates, by an employee, contractor or agent of yours or your affiliates for compensation for an invention assigned to Pfizer under this contract. 

  

	8.	CONFIDENTIALITY 

  

	 	(a)	Using the same standards you use to protect your own information, you must keep confidential: (i) the written specifications, instructions and operating procedures Pfizer gives
you; (ii) the data and other information you produce for Pfizer; and (iii) any other information that Pfizer gives you and tells you is confidential. You may only use this information, and disclose it to your employees, as necessary for
you to perform services under this contract. You must not disclose this information to a third party. But, you may disclose this information to the extent that your lawyer determines the law requires disclosure as long you first notify Pfizer and
cooperate in any attempt by Pfizer to obtain a protective order. 

  

	 	 (b)
	 These restrictions will not apply to information that becomes public knowledge through no fault of yours or information
that you already have or obtain outside of this contract even though it is of the same or similar content. The restrictions will end * after this contract
ends. 

  

	9.	EH&S 

 It is very important to Pfizer that its
contractors comply in all respects with applicable environmental, health and safety (EH&S) and any related guidelines or operating procedures Pfizer gives you. Accordingly, you must: 
  

	 	(i)	give to Pfizer any information Pfizer requests that relates to the environmental, health and safety aspects of your operations. 

  

	 	(ii)	comply with the applicable laws, guidelines and operating procedures and indemnify Pfizer against any liability Pfizer incurs because you fail to comply with them.

  

	 	(iii)	perform services under this contract in a safe and ethical manner (including the storage, handling and disposal of any hazardous materials). 

  

	 *
	 Indicates that certain information contained herein has been omitted and filed
separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  

 4 

	 	(iv)	notify Pfizer if, at any time, you are not compliant with the laws, guidelines and operating procedures and the non-compliance poses a significant threat to the environment or
health. 

  

	 	(v)	immediately take corrective steps if, at any time, Pfizer notifies you that your conduct of services does not comply with the applicable laws, guidelines or operating procedures.

  

	10.	RELATIONSHIP WITH PFIZER 

  

	 	(a)	You are an independent contractor. Your employees have no right to receive compensation from Pfizer or participate in any Pfizer benefit plans. You are solely responsible for all
liabilities, costs and all other aspects of your staff’s employment. 

  

	 	(b)	Neither you nor your employees have the power to act on Pfizer’s behalf or bind Pfizer in any way. Further, neither you nor your employees will represent to anyone that you
have such power. 

  

	11.	IMMIGRATION 

 It is very important to Pfizer that
you comply with all applicable immigration laws. You will indemnify Pfizer against any liability Pfizer incurs because you fail to comply with such laws. 
  

	12.	SUBCONTRACTING 

 You must not use subcontractors
except for your wholly owned subsidiaries to perform services under this contract without Pfizer’s written permission. If Pfizer gives permission, you will be responsible for the subcontractor’s performance and compliance with this
contract. 
  

	13.	INSURANCE 

 Throughout the contract you must
maintain the insurance coverage required by Pfizer’s Contractor Insurance Guidelines. If you do not have a copy of these guidelines you must notify Pfizer and Pfizer must give you a copy. 
  

	14.	LIMITATION OF LIABILITY 

 Neither party will be
liable to the other under this contract, whether in tort, contract or otherwise, for any indirect or consequential losses or any punitive or exemplary damages. 
  

	15.	TERM AND TERMINATION 

  

	 	(a)	 This contract will continue until terminated or replaced. After six months from the date of this contract, either party may terminate this contract without cause by
giving the other 30 days written notice. Pfizer’s only obligation will be to pay you 

  

 5 

	 	 
for services completed, and non-cancelable expenses you have incurred at Pfzer’s request, prior to termination. You must return to Pfizer the balance of
any payments made by Pfizer in excess of this obligation. Non-cancelable expenses are those expenses that you can not reasonably avoid or deploy for the benefit of other operations. They will not include staff costs but may include raw materials.
Pfizer and you will negotiate the amount of any such expenses in good faith. But, the amount plus any other payments made by Pfizer under an order may not exceed the total price of the order. 

  

	 	(b)	If either party breaches this contract, the other may terminate it if the breaching party does not cure the breach within 30 days of written notice. Termination will be without
prejudice to any rights which may have accrued to either party before termination. 

  

	 	(c)	On termination of this contract for any reason you must return to Pfizer, at Pfizer’s expense, all materials, laboratory notebooks, other documents or confidential information
Pfizer has given to you or you have produced for Pfizer. If any information or documents are not in a returnable form you must delete or render them unreadable if practical; otherwise you must clearly mark them “Pfizer Confidential”.

  

	16.	PUBLICITY 

 Neither you nor Pfizer may publicize
this contract without the other’s permission. You must not use Pfizer’s name in connection with any form of promotion without Pfizer’s prior written permission. 
  

	17.	ANTI-CORRUPT PRACTICES 

 It is very important to
Pfizer that you do not make any illegal payments to third parties (eg. bribery of government officials) in connection with the services. Accordingly, so that Pfizer can investigate the lawfulness of any payments you make to third parties in
connection with the services, you must maintain records of such payments for at least three years after completion of the relevant services. 
  

	18.	AUDITS 

  

	 	(a)	To verify your compliance with this contract, Pfizer may audit you upon giving you reasonable notice. Any audit will include the right to inspect any facility being used by you for
the services and to inspect all relevant records. You must co-operate fully with Pfizer during any audits. 

  

	 	(b)	Pfizer must keep confidential any information that we obtain when we audit you and that you tell us is confidential. Pfizer may only use this information, and disclose it to its
employees and advisers, as necessary for Pfizer to exercise its rights under this contract. Pfizer must not disclose this information to a third party. This restriction will end seven years after the relevant audit. 

  

 6 

	19.	GENERAL 

  

	 	(a)	Assignment. Pfizer may assign, in whole or in part, its rights and obligations under this contract to any affiliate without your consent. Otherwise, neither you nor Pfizer
may assign any of their rights or obligations under this contract without the other’s prior written permission. 

  

	 	(b)	Notices. All notices will be in writing and sent by certified mail, return receipt requested, courier, or facsimile. Notices will be deemed given on the date they are
received. Notices to Pfizer must be sent to the address noted on the signature page and marked for the attention of President, PGRD with a copy to General Counsel, PGRD. Notices to you must be sent to the address noted on the signature page and
marked for the attention of CEO with a copy to General Counsel. 

  

	 	(c)	Severability. If any provision of this contract is invalid or is unenforceable, the parties intend that the remainder of the contract will be unaffected.

  

	 	(d)	Waiver. A party’s compliance with the terms of this contract may only be waived by written notice from the other party. Unless stated otherwise a waiver will not be
deemed an ongoing waiver. Any delay or failure of a party to require performance of a term of this contract will not prevent the party from enforcing the term later. 

  

	 	(e)	Force Majeure. A party will not be in breach or liable for any failure of delay of its performance of this contract caused by natural disasters or circumstances reasonably
beyond its control. 

  

	 	(f)	Binding Effect. This contract will be binding upon and shall inure to the benefit of Pfizer and you, and Pfizer’s and your respective successors and permitted assigns.

  

	 	(g)	Governing Law. This contract is to be construed and determined under the laws of the People’s Republic of China. Any dispute between the parties will be finally resolved
by binding arbitration under the Rules of Arbitration of the China International and Trade Arbitration Commission (“CITEAC”) or if CITEAC does not have jurisdiction then the arbitration rules of the International Chamber of Commerce
(“ICC”). Any arbitration will be conducted in the English language and be conducted at a mutually agreed location in the Hong Kong Administrative Region of the People’s Republic of China. 

 AGREED: 
  

									
	Signed on behalf of each of the following companies or entities: WuXi PharmaTech Co., Ltd	 		 	Signed on behalf of Pfizer Inc.,:
					
	By:	  	  
	 		 	By:	 	  

	Name:	  	  
	 		 	Name:	 	  

	Title:	  	  
	 		 	Title:	 	  

	Date:	  	  
	 		 	Date:	 	  

			
	 Address: 
  
 Building 1, #288 Fu Te Zhong Lu
 WaiGaoQiao Free Trade Zone
 Shanghai 200131, China
	 		 	 Address: 
  
 Pfizer Global R&D Headquarters
 50 Pequot Avenue
 New London, CT 06320

  

 7 

 WUXI PHARMATECH CO., LTD 
 * SERVICES CONTRACT - 
 * 
 Appendix A: Description of Services 
  

	A.	SERVICES 

  

	1.	* INTRODUCTION 

 The * Pilot described in this
appendix is part of a larger effort by Pfizer Global Research and Development to explore the R&D potential of Asia. The overall objective of the pilot is to increase the *, * and * of the drug discovery process through the * of * services in
China. The services described below are related to the provision of * screening services and include *. 
  

	2.	WuXi PharmaTech SERVICES 

 Both Pfizer and you
acknowledge that there are considerable uncertainties with respect to the duration, scope and operation of the * Pilot that may require the Pilot to be expanded, reduced, extended, terminated or otherwise adjusted. Accordingly, a Steering
Committee will be established with at least two representatives from each company to meet regularly (at least monthly) to review and discuss the progress of the Pilot and your services and make any adjustments that may be needed (including the start
and end dates, processes and procedures, capacity and pricing). 
 WuXi PharmaTech will perform the * screening for the *
Pilot. This * will require you to establish a * Assay and a * Assay as described below, dedicate certain FTEs and Bioanalytical equipment as described below, and screen the number of samples required by the protocols
referred to below for up to * compounds per week. Initially, Pfizer will direct to you all the compounds for * screening from a single Pfizer * project. Given inherent uncertainties in the conduct of * projects the number
of compounds directed to you for screening on week to week basis will vary. It is estimated that the weekly requirements for compounds screening will range from * compounds. 
 It is anticipated that your screening will commence by March 15, 2007 and that your support of the * Pilot will last 3 to 6 months. Before the
end of the first 3 months after your screening has commenced the Steering Committee will meet to conduct a detailed review of the Pilot and to determine whether the Pilot will be extended for an additional three months or such other period as the
parties agree. 
 If, on conclusion of the * Pilot, Pfizer decides to proceed with the sourcing of * services in China, Pfizer and you will negotiate in good faith to establish a longer term contract for the routine
supply of these services that will address capacity commitments and other operational matters to reflect the parties’ learnings from the Pilot. Longer term contract pricing will be set per Appendix B, Section 5. 
  

	 *
	 Indicates that certain information contained herein has been omitted and filed
separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  

 1 

	B.	SPECIFICIATIONS, PROCESSES AND PROCEDURES 

  

	1.	MATERIALS MANAGEMENT 

  

	 	(a)	Throughout the course of the*Pilot, Pfizer will provide compounds to you for testing purposes. You will be responsible for storing and handling the compounds in accordance
with Pfizer protocols and all appropriate laboratory techniques; 

  

	 	(i)	All compounds not actively being used in an assay must be stored 

  

	 	1)	at * OR 

  

	 	2)	* 

  

	 	(ii)	Reasonable care must be given to limit exposure of the compounds to * 

  

	 	(iii)	Reasonable care must be taken to ensure compounds remain in solution before use in an assay. 

  

	 	(iv)	Reasonable care must be taken to limit wastage of compound material. 

  

	 	(v)	* libraries and * compounds undergoing * screening will be produced internally by Wuxi chemists. Wuxi will set aside an aliquot sample for use in * screening.

  

	 	(vi)	Pfizer will ensure sufficient material is provided to you for executing the assays. 

  

	 	 (b)
	 Throughout the course of the * Pilot Pfizer will provide you with select lists of compounds to be tested. These lists may include * You will prepare assay plates according to the list of compounds requested for testing. 

  

	 	(c)	You will maintain accurate records on the well locations of all compounds provided to you by Pfizer 

  

	2.	ASSAY VALIDATION 

  

	 	(a)	You will establish the * Assay and * Assay at your local facilities. 

  

	 	(b)	You will validate the * Assay and * Assay using control compounds and validation criteria specified by Pfizer. 

  

	 	(c)	Pfizer will provide you with protocols for the * Assay and * Assay. 

  

	 	(d)	Pfizer will work with you to adapt the assay protocols to your specific facilities and equipment. 

  

	 *
	 Indicate that certain information contained herein has been omitted and filed
separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  

 2 

	 	(e)	Assays will be validated based upon the following metrics; 

  

	 	 (i)
	 * Assay

  

	 	1)	* minutes 

  

	 	2)	* minutes 

  

	 	(ii)	* Assay 

  

	 	1)	* inhibition for each * 

  

	 	2)	Week to week *% of * <*% 

  

	 	(f)	All changes to assay protocols OR quality metrics must be approved by Pfizer prior to implementation. 

  

	3.	ASSAY EXECUTION 

  

	 	(a)	You will execute the * Assay and * Assay for all compounds requested by Pfizer in accordance with the validated protocols. 

  

	 	(b)	You will provide Pfizer with assay data within *-week of receiving the compounds and associated compound testing lists. 

  

	4.	BIOANALYTICAL EQUIPMENT 

  

	 	(a)	For the duration of the * Pilot you will dedicate one * machine to the analysis of Pfizer samples. 

  

	 	(b)	You will provide Pfizer additional flexible capacity equal to *% of one * machine’s analytical time. Pfizer may adjust the level of flexible capacity as needed throughout the
course of the project. 

  

	 	(c)	Pfizer will provide*-weeks notice for any downward adjustments to flexible capacity. Any upward adjustments in flexible capacity will be contingent upon the availability of these
resources. 

  

	 	(d)	Pfizer will work with you to optimize your * protocols for use in the Pfizer assays. These protocol adjustments may include changes to programming, equipment configurations
or * processes. 

  

	 	(e)	You will be responsible for the maintenance and upkeep of all machinery and equipment used in the analysis of Pfizer samples. If any dedicated Pfizer equipment goes out of service
you will provide Pfizer an equivalent replacement. 

  

	 *
	 Indicate that certain information contained herein has been omitted and filed
separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  

 3 

	5.	DATA ANALYSIS 

  

	 	(a)	You will provide Pfizer with Raw Data, Analyzed Data and Quality Metrics for all compounds and assay plates tested. 

  

	 	 (i)
	 Raw Data is defined as the * areas values for each data point 

  

	 	(ii)	Analyzed Data is defined as the calculated end-point data for each compound. 

  

	 	1)	* Assay end-point are half-life 

  

	 	2)	* Assay end-points are %Inhibition 

  

	 	(iii)	Validation Metrics include the following 

  

	 	1)	* Assay* 

  

	 	2)	* Assay * 

  

	 	3)	* Assay % Inhibition for each * 

  

	 	(b)	Pfizer will specify the preferred data format for Raw Data, Analyzed Data, and Quality Metrics 

  

	 	(c)	Pfizer will provide you with sample templates for Raw Data, Analyzed Data and Quality Metrics 

  

	 	(d)	You will provide the electronic data files (Raw Data, Analyzed Data and Quality Metrics) to Pfizer in the delivery method Pfizer requests (e-mail, shared folder, etc).

  

	 *
	 Indicate that certain information contained herein has been omitted and filed
separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  

 4 

 WUXI PHARMATECH CO., LTD 
 * SERVICES CONTRACT - 
 * 
 Appendix B: Fees 
  

	1.	FTES 

  

	 	a.	Pfizer will fund * FTEs to support Pfizer’s *Pilot Project. The FTEs will be Bachelor of Science level or higher and have adequate training in bioanaltyical *
techniques and in vitro *. The specified monthly FTE rate is* including cost of reagents and supplies valued at less then * for each individual item. Pfizer will fund the FTEs for a period of * months starting on
*. The funded FTEs will provide the services outline in Appendix A. 

  

	 	b.	Pfizer reserves the right to reduce or eliminate the number of FTEs funded for the * Pilot Project at any time. 

  

	 	c.	In the event that Pfizer provides reagents or supplies (except those in Section 3.b), the cost of those supplies will credited to Pfizer and deducted from the summary monthly
invoice. 

  

	2.	BIOANALYTICAL EQUIPMENT 

  

	 	a.	Pfizer will fund one and one-half (1.5)* machines to provide dedicated support to Pfizer’s * Pilot Project. The * machines employed will be * or an
acceptable equivalent. The specified monthly rental rate is* and is inclusive of all ancillary equipment, maintenance and consumables used in the provision of the bioanalytical service highlighted in Appendix A.

  

	 	b.	Pfizer reserves the right to reduce or eliminate the number of * machines at any time. 

  

	3.	CONSUMABLES 

  

	 	 a.
	 Pfizer will reimburse WuXi PharmaTech for reagents or supplies that individually exceed *. Prior to purchasing, WuXi PharmaTech must receive written permission from Pfizer or expenses will not be reimbursed. 

  

	 	b.	Pfizer will supply WuXi PharmaTech with the following consumable items to be used solely on Pfizer projects: 

  

	 	i.	Test Compounds 

  

	 	ii.	* Racks 

  

	 	iii.	* Racks 

  

	 *
	 Indicates that certain information contained herein has been omitted and filed
separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  

 1 

  

	4.	OTHER FEES 

  

	 	a.	Payment of Freight 

  

	 	i.	WuXi PharmaTech will assume all * expenses for *, etc from * and other third party collaborators. Pfizer will assume all * expenses for *, etc
from * to * 

  

	 	b.	Taxes 

  

	 	i.	In performing the services defined in this contract, any sales tax, duty, or any other tax, fee or charge of any nature imposed by any governmental authority, shall be paid by
* 

  

	 	c.	Travel Expenses 

  

	 	 i.
	 Pfizer and WuXi PharmaTech will each bear all expenses, including reasonable travel, related to the * of *of the Steering Committee and any invitees to facilitate technical transfers. 

  

	 	d.	Other Costs 

  

	 	i.	All costs stated above are meant to be all inclusive. No other fees or costs will be paid by Pfizer without WuXi PharmaTech obtaining prior written consent from Pfizer.

  

	5.	INVOICING 

  

	 	a.	At the end of each month, WuXi PharmaTech will provide a summary monthly invoice of all service fees and credits. 

  

	 	b.	Pfizer’s P.O. terms and conditions will stipulate proper invoicing procedure, net payment terms, etc. 

  

	6.	* 

  

	 	a.	The prices described above reflect WuXi PharmaTech’s intention to receive an *for performing Pfizer’s * work of between *%-*%. If during the * Pilot WuXi PharmaTech
believes that the pricing above does not achieve this * it may raise the matter at the steering committee (providing such information and documentation as requested by Pfizer’s representatives) and Pfizer acting reasonably and in good faith,
will adjust the pricing to return the * project to a *%-*% * on an ongoing basis. 

  

	 	b.	If the * Pilot is successful and Pfizer decides to source * services in China, the parties agree in good faith that the pricing will not be renegotiated in future
contract negotiations and the * described in Section 5.a will prevail. 

  

	 *
	 Indicates that certain information contained herein has been omitted and filed
separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  

 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00127-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00127-of-00352.parquet"}]]